annual meeting 2011 clinical trial development clinical trial development: oewg, ra’s role, and...
TRANSCRIPT
![Page 1: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/1.jpg)
Annual Meeting 2011 Clinical Trial Development
Clinical Trial Development: OEWG, RA’s Role,
and Activating Trials on Deadline
Martha HeckelProtocol Associate II, ACRIN Dept. of Protocol Development
& Regulatory Compliance
![Page 2: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/2.jpg)
Annual Meeting 2011 Clinical Trial Development
Overview of Discussion Points
1. Introducing the OEWG Timeline
2. The RA in Early Trial Development
3. Trial Activation and Ramp-Up Phase
![Page 3: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/3.jpg)
Annual Meeting 2011 Clinical Trial Development
Introduction to OEWG
1. Introducing the OEWG Timeline:
• What is the OEWG?
• What is this about a timeline?
• How is it impacting ACRIN … the sites?
![Page 4: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/4.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG … What?
What is the OEWG?
OEWG = Operational Efficiency Working Group
Established in 2008, the OEWG assessed how the cooperative groups function … and suggested changes.
![Page 5: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/5.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG … Why?
Studies of timelines within the cooperative group structure show our processes can be improved …
Dilts DM, Sandler AB. Activating and Opening Oncology Clinical Trials: Process & Timing Analysis. Available at: www.iom.edu/~/media/Files/Activity%20Files/Disease/NCPF/Dilts.pdf; accessed September 7, 2011.
![Page 6: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/6.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG Timeline
The OEWG and CTEP have implemented target and absolute deadlines for concept development through actual trial activation.
Trial activation is defined as one site ready to accrue participants.
![Page 7: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/7.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG Timelines: Target
The OEWG guidelines include hard drop-dead dates depending on the phase of the treatment trial.
Trial Phase Target Deadlines Absolute Deadlines
Phase I 210 Days 540 Days
Phase II 210 Days 540 Days
Phase III 300 Days 720 Days
![Page 8: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/8.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG Timelines: Phases I and II
Target Milestones
![Page 9: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/9.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG and ACRIN
ACRIN will adhere to the same timelines, regardless of whether the trial is NCI funded or funded by another source (ACRIN Foundation, PA DoH, AHRQ).
ACRIN will always have to work within OEWG structure for cooperative trials with other groups (e.g., ECOG, GOG, or RTOG).
![Page 10: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/10.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG Timelines: Impact
Implications for ACRIN Procedures:
•More complete trial design prior to CTEP submission.
•Less complex trial designs.
•Forms and ancillary documents must be completed prior to activation.
– Medidata RAVE and standardization
![Page 11: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/11.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG and ACRIN
What changes have ACRIN and NCI introduced to meet the target deadlines?
A.Shift in timing (earlier, earlier, earlier)
B.Site membership
C.Scanner qualifications
D.Focus on activation/recruitment
![Page 12: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/12.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG and ACRIN
A. Shift in timing (earlier, earlier, earlier)• Delivery of materials
to sites (protocol summary, PSA, etc)
• Streamlined development/completion of forms
• Advanced oversight of contract negotiations
![Page 13: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/13.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG and ACRIN
B. Site membership
• Centers for QuantitativeImaging Excellence, or CQIE Program(advanced imaging qualification program—NCI-designated Cancer Centers only)
• ECOG/ACRIN and ECOG membership
![Page 14: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/14.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG and ACRIN
C. Scanner qualifications
• CQIE (CT, MR, PET)
• ACRIN will be working with sites to qualify imaging scanners using CQIE standards
![Page 15: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/15.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG and ACRIN
D. Focus on activation/recruitment
• Earlier description of trial to sites; allow as much time as possible to review and consider joining the trial
• Consideration of the multidisciplinary team needed to perform the trial• ECOG involvement will facilitate the
connection between oncology and radiology as we join with treatment trials
![Page 16: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/16.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG and ACRIN
D. Focus on activation/recruitment con’t
• Better understanding of sites’ processes, and how ACRIN can help …• How many committees
at your sites must review the protocol?
• On what timeline? • How can
ACRIN help?
![Page 17: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/17.jpg)
Annual Meeting 2011 Clinical Trial Development
OEWG and ACRIN
D. Focus on activation/recruitment con’t
• Review of PSAs by multiple ACRIN departments and the trial PIs—plans for accrual
• Make sure sites aware of all open ACRIN trials
![Page 18: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/18.jpg)
Annual Meeting 2011 Clinical Trial Development
After Trial Activation
TRIAL ACTIVATES!
![Page 19: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/19.jpg)
Annual Meeting 2011 Clinical Trial Development
2. The RA in Early Trial Development:
– Design:• Consider Role of RA Committee Rep
(Scientific and Procedural Input)• Review of Protocol Contents
– Implementation at sites:• Anticipate Obstacles to Avoid
Protocol Violations• Ponder: What Tools Would Help Trial Process?
During Early Trial Development
![Page 20: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/20.jpg)
Annual Meeting 2011 Clinical Trial Development
Trial assigned to a representative from the RA Committee
RA Committee reps instrumental in forms development,which will have greater impact going forward …
RA Committee Rep’s Role
![Page 21: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/21.jpg)
Annual Meeting 2011 Clinical Trial Development
Every RA has a role in trial development:• Translation to local implementation• Reasonable timelines for procedures• Identifying pitfalls
(obstacles to studycompliance)
And let us know at any time when you see areas for improvement
Development and Implementation
![Page 22: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/22.jpg)
Annual Meeting 2011 Clinical Trial Development
Representative reviews the protocol/forms from data collection/operations perspective:
• How well are the procedures defined?• Is the protocol consistent?• What might be
confusing to an RA (missing details)?
During Trial Development
![Page 23: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/23.jpg)
Annual Meeting 2011 Clinical Trial Development
During Trial Development
How Can ACRIN Help You?Help the Trial?
During trial development, chime in with ideas to assist the trial:
• Eligibility flip charts
• Patient handouts
• Screening log
![Page 24: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/24.jpg)
Annual Meeting 2011 Clinical Trial Development
During Trial Development
“I have ideas! Who’s my contact?”
ACRIN’s Project Managers and Communications team leads the development of recruitment and other study-related materials.
Call Nancy Fredericks to get started!
![Page 25: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/25.jpg)
Annual Meeting 2011 Clinical Trial Development
3. Trial Activation and Ramp-Up Phase:Once the initial protocol is approved,
ACRIN requests for local IRB submission no more than 30 days from receipt … maybe less depending on OEWG timeline!
For amendments, ACRIN allows 60 days for protocol approval.
Submitting to Local IRBs
![Page 26: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/26.jpg)
Annual Meeting 2011 Clinical Trial Development
During Trial Development
Trial Development Is an Ongoing Process
• The conduct of the trial is important!
• We hope you will join our Site t-con calls and training.
• Contact us any time if you have specific feedback, e.g.,see trends within a specific trial or across ACRIN trials.
![Page 27: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/27.jpg)
Annual Meeting 2011 Clinical Trial Development
“Why the push? Don’t we have 60
to 90 days for approval?”
Yes, technically …But amendments are
often in response to site feedback to eliminate accrual barriers or provide clarification.
So, the sooner, the better!
Submitting to Local IRBs
![Page 28: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/28.jpg)
Annual Meeting 2011 Clinical Trial Development
ACRIN trials would not be successful without our dedicated RAs.
Thank you all for your commitment to ACRIN trials and the people
who participate.
We couldn’t do it without YOU!
Thank You
![Page 29: Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate](https://reader037.vdocuments.site/reader037/viewer/2022102808/56649e435503460f94b362dc/html5/thumbnails/29.jpg)
Annual Meeting 2011 Clinical Trial Development
Questions?